Going beyond
the common twenty.
the common twenty.
Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the existing 20 natural amino acids, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.
Breakthrough Protein Therapeutics
Growth in the protein pharmaceutical market is going to be driven by the development of next-generation therapeutic proteins that are safer and longer acting. Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.Antibody Drug Conjugates
Antibody drug conjugates (ADCs) allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high potency and a significantly wider therapeutic index than ADCs created using conventional non-specific conjugation.News
May 3, 2013Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
More News
© Copyright 2006-2012 Ambrx Inc. All right reserved.